Home › Therapeutic areas › Metabolic

Metabolic (52 companies · 42 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In Metabolic Lead stage Mkt cap Programs
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $25.2M 3
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 1 Approved $1.79B 7
ALT Altimmune GI/HepatologyMetabolic+1 1 Phase 3 $298M 3
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 4 Phase 3 $3.54B 5
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 2 Phase 2 $2.14B 6
BLTE Belite Bio MetabolicOphthalmology Rare 4 NDA Submitted $6.35B 6
BMEA Biomea Fusion MetabolicOncology 3 Phase 2 $35.5M 4
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 1 Phase 1 $249M 9
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 1 Phase 2 $13.2M 4
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 4 Approved — 6
DYN Dyne Therapeutics MetabolicNeurology Rare 1 NDA Submitted $3.00B 10
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 1 Phase 2 $167M 3
ENTX Entera Bio GI/HepatologyMetabolic Rare 3 Phase 2 $522M 4
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 8 Approved $1.84B 17
FBIO Fortress Biotech DermatologyHematology+4 Rare 3 Approved $61.4M 16
GUTS Fractyl Health Metabolic 1 Phase 3 $12.8M 1
GANX Gain Therapeutics MetabolicNeurology Rare 1 Phase 1 $52.5M 5
HRMY Harmony Biosciences MetabolicNeurology Rare 2 Approved $1.94B 17
IMCR Immunocore DermatologyInfectious Disease+2 1 Approved $1.44B 12
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 1 Approved $4.49B 29
KURA Kura Oncology MetabolicOncology 2 Approved $688M 13
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $207M 13
MAZE Maze Therapeutics MetabolicRenal Rare 2 Phase 2 $1.80B 4
MBX MBX Biosciences Metabolic Rare 4 Phase 3 $2.64B 4
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 3 Phase 3 $827M 16
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 1 Phase 2 $775M 7
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.23B 11
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 1 NDA Submitted $2.33B 6
PTN Palatin Technologies ImmunologyMetabolic+1 1 Phase 3 $9.5M 5
PYPD PolyPid Infectious DiseaseMetabolic+1 1 NDA Submitted $138M 4
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 2 Phase 1 $197M 5
PRQR ProQR Therapeutics MetabolicNeurology Rare 2 Phase 1 $163M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 3 Approved $8.14B 12
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $143M 3
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $321M 4
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 1 Phase 3 $4.7M 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 14 Approved $8.08B 14
SABS SAB Biotherapeutics Metabolic 1 Phase 2 $266M 1
SGMT Sagimet Biosciences DermatologyMetabolic 1 Phase 3 $709M 3
SANA Sana Biotechnology MetabolicOncology 2 Phase 1 $563M 4
SEPN Septerna ImmunologyMetabolic+1 Rare 1 Phase 1 $1.90B 5
SPRB Spruce Biosciences Metabolic Rare 2 Preclinical $116M 2
GPCR Structure Therapeutics MetabolicRespiratory Rare 4 Phase 3 $3.90B 5
TVTX Travere Therapeutics MetabolicRenal Rare 1 Approved $4.91B 7
TYRA Tyra Biosciences MetabolicOncology Rare 1 Phase 2 $1.35B 5
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 8 Approved $1.70B 10
QURE uniQure HematologyMetabolic+1 Rare 1 Approved $1.46B 4
VKTX Viking Therapeutics MetabolicNeurology Rare 6 Phase 3 $3.43B 9
VYGR Voyager Therapeutics MetabolicNeurology Rare 1 Phase 1 $94.6M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 4 Phase 3 $69.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 2 Phase 2 $560M 5
XERS Xeris Biopharma MetabolicNeurology Rare 3 Approved $3.07B 4